This study sought to evaluate the outcome of maternal autoantibody-mediated fetal cardiomyopathy/endocardial fibroelastosis following intravenous gamma globulin (IVIG) and corticosteroid therapy.
Background
We have previously shown that 85% of fetuses and infants with maternal autoantibody-mediated fetal cardiomyopathy/endocardial fibroelastosis suffer demise or need for transplant. In an attempt to improve this outcome, in 1998, we began to empirically treat affected patients with IVIG and corticosteroids.
Methods
We reviewed the clinical records and echocardiograms of 20 affected patients encountered in our institutions and treated with IVIG and corticosteroids from 1998 to 2009.
Results
All 20 were initially referred at a median gestational age of 23 weeks (range 18 to 38 weeks). Nineteen mothers were anti-Ro antibody positive, 8 anti-La antibody positive, and 7 had clinical autoimmune disease. Endocardial fibroelastosis was seen in 16 and was not obvious in 4 others with reduced ventricular function, and 16 (80%) had reduced or borderline ventricular shortening fraction (Յ30%) before or after birth. Eighteen had atrioventricular block at referral (16 in 3°) . During pregnancy, maternal IVIG was given in 9 and dexamethasone in 17. After birth, 17 infants received IVIG (n ϭ 14) and/or corticosteroids (n ϭ 15). Twelve underwent pacemaker implantation. Four with hydrops at presentation died perinatally, despite initial improvement in function in 3. At a median follow-up of 2.9 years (1.1 to 9.8 years), 16 (80%) patients are currently alive with normal systolic ventricular function and 6 are not paced.
Conclusions
Treatment of maternal autoantibody-mediated fetal cardiomyopathy/endocardial fibroelastosis with IVIG and corticosteroids potentially improves the outcome of affected fetuses. Further studies are needed to determine the optimal dose and timing of IVIG administration. Anti-Ro(SSA) and anti-La(SSB) antibodies are found in patients with autoimmune diseases including systemic lupus erythematosus (SLE) and Sjögren syndrome (1) , but may also be identified in pregnant women without autoimmune disease (2) . Neonatal lupus erythematosus results when these maternal autoantibodies (MAb) pass through the placenta and deposit on fetal tissues, including the heart (3, 4) . Clinical fetal myocardial disease is observed in 1% to 2% of pregnancies with MAb, typically between 20-and 24-weeks gestational age (GA) (5) . In most affected fetuses, myocardial damage is largely confined to the conduction system with evolution of atrioventricular block (AVB). Approximately 20% of affected fetuses, however, can develop more diffuse myocardial disease manifested as cardiomyopathy (CM) and usually associated with endocardial fibroelastosis (EFE) (2, 6, 7) , and this may occur with or without clinical conduction system abnormalities. The prognosis for fetuses and infants with diffuse MAb-CM/EFE is generally poor, with death or need for cardiac transplantation in 85% despite successful pacemaker therapy (6) (7) (8) . A standard treatment approach in pregnancies with MAbrelated fetal disease, including maternal dexamethasone and betasympathomimetic therapy in conjunction with more aggressive surveillance and perinatal management, has been shown to decrease morbidity and improve outcomes (9) . A closer look at our previous series, however, reveals that fetuses who developed MAb-CM/EFE despite dexamethasone and beta-sympathomimetics were responsible for 80% of all fetal deaths and 44% of post-natal deaths or cases requiring cardiac transplantation (9) .
In 1998, a new treatment strategy of administrating intravenous gamma globulin (IVIG) and corticosteroids, either before or after birth, following a diagnosis of fetal MAb-CM/EFE was initiated. Use of IVIG was justified based on our discovery of diffuse immunoglobulin (Ig) G deposition, IgM, and T-cell infiltration throughout the myocardium, suggesting MAb induces a fetal immune response leading to CM/EFE (6, 7) . In fact, of the patients with MAb-CM/ EFE described in our previous report (6) , the only fetal survivor received IVIG shortly after birth. Additionally, the use of IVIG and corticosteroids to treat other inflammatory disorders, such as SLE and Sjögren syndrome, has been well described (10, 11) . We hypothesized that fetuses and infants with MAb-CM/EFE treated with IVIG and corticosteroids would have better outcomes than those treated with corticosteroids alone. This study reports the outcomes of this novel treatment strategy as experienced in 4 fetal and neonatal treatment centers with comparison to historical controls.
Methods
This study was a multicenter, retrospective review that included patients from the University of California, San Francisco; the Hospital for Sick Children, Toronto, Ontario; the University of California, Davis, Sacramento; and the Heart Institute for Children, Oak Lawn, Illinois. We included all fetuses and infants of mothers with anti-Ro and/or anti-La antibodies with evidence of MAb-CM/EFE defined by the presence of obvious EFE by echocardiography and/or myocardial systolic dysfunction. All were treated with IVIG and corticosteroids before or after birth. Fetuses and infants with and without AVB and those with simple congenital heart defects were included. Patients with isolated AVB without CM or EFE, and those with more complex structural heart disease were excluded.
The clinical presentation, management, and outcome of 20 consecutive cases of MAb-CM/EFE encountered from 1998 to 2009 were reviewed. Clinical data collected included GA at diagnosis of fetal heart disease; AVB severity; timing, type, and dose of therapy; GA at birth; age at pacemaker insertion, subsequent interventions, and at most recent follow-up; age at time of death; and cause of death. Maternal data collected included MAb positivity, presence of clinical autoimmune disease, age at pregnancy, previously affected children, and medications and doses received during pregnancy.
Echocardiographic parameters collected pre-natally included atrial and ventricular rates, ventricular systolic function, severity of tricuspid and mitral insufficiency, and the presence of any structural heart defects. In cases where the fetus was not in AVB, the AV interval (reflecting PR interval) was also measured using previously validated Doppler techniques (12) . Fetal 3°AVB was diagnosed in cases where there was no mechanical relation between atrial and ventricular contraction (13) . Ventricular shortening fraction (SF) was calculated with comparison to normal values and considered abnormal if Ͻ28% or borderline in 3°A
VB if 28% to 30% (14) . Endocardial fibroelastosis was suspected when echogenic areas within the endocardium of atria and ventricles, papillary muscles, and chordae were identified (6), and it was further categorized by severity (Fig. 1) . Post-natal echocardiograms were also reviewed to document valve insufficiency, degree and location of EFE, ventricular function (SF by M-mode and ejection fraction, available consistently in last exam, by biplane Simpson), and presence of structural heart disease. Autopsy findings were reviewed. The research ethics boards of the participating institutions approved this investigation. Statistical analysis. Simple statistics were calculated using Microsoft Excel for Mac (version 11.2.3, Microsoft Corp., Redmond, Washington). Table 1 details the characteristics of the 20 patients encountered. Eighteen were from singleton pregnancies and 2 were dichorionic, diamniotic twins. The 19 pregnancies were diagnosed with fetal cardiac disease at a median GA of 23 weeks (range 18 to 33 weeks). Fetal echocardiography referral was for fetal bradycardia in 17 (85%) and suspected CM/EFE in 3 (15%). Median maternal age was 29 years (22 to 38 years). Nineteen mothers were anti-Ro and 8 anti-La antibody positive. For one other with SLE referred at 38 weeks for delivery, specific antibody type was not available. Seven mothers had clinical autoimmune disease: 5 SLE, 1 hypothyroidism, one rheumatoid arthritis. Twelve were clinically asymptomatic. One mother had a previous infant with AVB.
Results

Clinical features.
At initial referral, 16 fetuses had 3°AVB, 1 had 2°AVB, 1 had 1°AVB, and 2 had a normal atrial rhythm with a normal AV interval. Endocardial fibroelastosis was identified in 16 (13 pre-natally, 3 post-natally) and was considered qualitatively severe in 3, moderate in 6, and mild in 7. MAb-CM/EFE was suspected in 4 others with myocardial systolic dysfunction but without obvious myocardial echogenicity. Reduced or borderline left, right, or biventricular SF was present in 11 fetuses at presentation or pre-natal follow-up. Five with 3°AVB developed hydrops (2 with small effusions, 3 with moderate-large effusions and/or ascites), and 1 in 3°AVB had an isolated pericardial effusion (Table 1) . Five others presented either in the neonatal period (n ϭ 3) or early infancy (n ϭ 2) with left ventricular systolic dysfunction and symptoms of heart failure. Management and clinical outcomes. Pre-natal and postnatal medical therapies for each patient are described in Table 2 . No pregnancy was electively terminated. In 16, maternal dexamethasone was administered at diagnosis of AVB (n ϭ 13) or MAb-CM/EFE (n ϭ 3). In another, prednisone was initially administered for fetal AVB at the referring institution, but was replaced with dexamethasone after referral to our institution. Two other mothers not given dexamethasone were both initially treated at outside institutions and only referred late to our programs. One patient (#16) developed transient oligohydramnios on dexamethasone that resolved spontaneously by 34 weeks. Dexamethasone therapy was otherwise well tolerated in all pregnancies. Beta-sympathomimetic therapy was initiated in 9 (47%) mothers for fetal ventricular rates of Ͻ55 beats/min, myocardial dysfunction, and/or evolving hydrops. Although oral beta-sympathomimetic therapy was well tolerated, 1 mother developed symptomatic sinus tachycardia (#14) upon conversion to the subcutaneous form, which improved with a dose reduction from 250 g to 130 g given every 4 h. One fetus developed ventricular ectopy (#15) that resolved with a dose reduction, and another developed atrial flutter that resolved with maternal digoxin (#16).
Intravenous gamma globulin was administered prenatally to 9 (47%) mothers at a dose of 70 g (ϳ1 g/kg). Three received a single dose, 3 received 2 pre-natal doses, and 3 received 3 or more doses. Multiple doses were used in the setting of worsening or persistent bradycardia and ventricular dysfunction. Of 9 with maternal IVIG and corticosteroid therapy, 6 demonstrated improved ventricular systolic function within 1 to 3 weeks of treatment. In 3 hydropic fetuses, however, improved systolic function and reduced effusions were only transient (2 to 3 weeks), and 1 demised at 23.5 weeks. Three others without hydrops had improved function at birth, and in 1, the severity of EFE lessened (#20). In 2, ventricular SF and EFE severity did not change through gestation. Four fetuses had improvement in AV conduction (Table 3) , all with maternal dexamethasone and 2 with maternal IVIG therapy. In 2 others with dexamethasone only, AVB progressed.
Fourteen of 19 live-born infants were delivered pre-term (28.4 to 37 weeks GA). After delivery, 9 had reduced or borderline ventricular SF. One other was so critically ill, a post-natal echocardiogram had not been performed prior to demise. Nine received isuprel for the treatment of severe bradycardia, and 6 received other medications including inotropes, bicarbonate, surfactant, and calcium (Table 2) . Twelve neonates (63%) underwent permanent pacemaker implantation at a median age of 26 h (range 1 h to 7 days), for dual mode, dual pacing, dual sensing (DDD) (n ϭ 4) or ventricular inhibited (VVI) (n ϭ 8) pacing (Table 3) . DDD pacing was chosen, particularly in the term neonates to *Gestational age at time of interuterine demise. †Twin gestation, both fetuses affected. AVB ϭ atrioventricular block; EFE ϭ endocardial fibroelastosis; GA ϭ gestational age; IUD ϭ interuterine demise; LV ϭ left ventricle; mat ϭ maternal; N/A ϭ not applicable; NB ϭ newborn period; ND ϭ neonatal death; post ϭ post-natal diagnosis; pre ϭ pre-natal diagnosis; RV ϭ right ventricle; SF ϭ shortening fraction; SLE ϭ systemic lupus erythematosus. provide atrioventricular synchrony. One critically ill premature neonate who arrested pre-operatively had concomitant placement of a VVI permanent pacemaker and temporary epicardial atrial and ventricular wires for DDD pacing. He was DDD paced using the temporary wires for nearly 2 weeks and converted to VVI mode using the permanent pacemaker following improvement in ventricular function. Two patients experienced wound infections, and 1 developed an incisional hernia that required repair. Eleven neonates received IVIG within the first few days, and 15 received steroids. In 6, ventricular systolic function normalized after IVIG and steroid therapy, pacemaker therapy, and, in 1, coarctation repair (at 3 days, #6). Only 2 required anticongestive therapy at discharge, which was discontinued within 6 months. Two hydropic fetuses (#14, #15) demised within the first day despite pre-term delivery and aggressive resuscitation, and a third (#4) had care withdrawn for severe neurological injury. Endocardial fibroelastosis was confirmed at autopsy in all 3. In 2, diffuse elastin and collagen deposition in the endocardium was demonstrated.
Two infants with neonatal pacemaker therapy presented at 2 to 3 months of age with clinical heart failure (#10, #18). Both subsequently received IVIG and steroids, and 1 had device closure of an atrial septal defect and conversion to biventricular pacing. One other (#16) presented at 2.5 months with acute EFE-related chordal rupture leading to severe mitral insufficiency and reduced left ventricular systolic function, as previously reported (15) . IVIG and steroids were administered and the infant underwent mitral valve repair. All 3 had normal ventricular SF within 2 weeks to 4 months of treatment.
Sixteen (80%) patients are currently alive. None has required cardiac transplantation. Patient #12 experienced lead fracture at 15 months necessitating reoperation and had concomitant suture repair of an atrial septal defect. Another patient (#12) required pericardiotomy for persistent pericardial effusion after lead replacement at 2 years. At most recent follow-up (median age: 2.9 years, 1.1 to 9.8 years), all 16 were found to have normal myocardial function (left ventricular ejection fraction: median 69%, range 61% to 73%; shortening fraction: Ͼ32%). Six patients are not paced.
Discussion
This is the first report describing the use of both IVIG and corticosteroids in the treatment of fetuses and infants with MAb-CM/EFE. Overall, patient survival was 80%, all with normal ventricular function at most recent follow-up. This represents a marked improvement when compared with historical controls from 3 series where 25 of 32 (78%; range 69% to 100%) reported died or required cardiac transplan- Dual-chamber 3°AVB, DDD paced *Patient with cardiac arrest en route to the operating room necessitating 45-min cardiopulmonary resuscitation. This was the only patient to have temporary pacing as well as placement of permanent single-chamber pacemaker. All others had permanent pacemaker insertion at initial operation. DDD ϭ dual mode, dual pacing, dual sensing; HR ϭ heart rate; VVI ϭ ventricular inhibited; other abbreviations as in Table 1 .
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tation (6 -8), 81% mortality if our first treated case was excluded (6) . MAb-CM/EFE pathogenesis. MAb-CM/EFE is a rare and poorly understood disorder of the endomyocardium that can lead to the development of congestive heart failure and death (6, 16, 17) . Pathologic evaluation reveals collagen and elastin deposition, ventricular hypertrophy, and diffuse endocardial thickening (7, 18) . The finding of MAb-CM/ EFE in the absence of AVB and evolution of late MAb-CM/EFE despite adequate pacing has suggested that CM/ EFE and AVB may be 2 separate disease manifestations in neonatal lupus erythematosus (7, 8) . In general, MAbmediated fetal heart disease is believed to be due to the transplacental passage of MAb anti-Ro and anti-La, which infiltrate fetal myocardial and specialized conductive tissue, leading to subsequent inflammation (19) . Evidence for an inflammatory component in the evolution of MAb-CM/ EFE has been demonstrated in autopsy specimens of patients with AVB who have scattered foci of mononuclear inflammatory cells and occasional B-cells in the myocardium (7, 20) . Myocardial IgG and complement deposition has also been reported (7, 21) . Interestingly, our previous discovery of IgM deposition and T-cell foci (CD43 and CD8 positive cells, T-cell activation) provide further support for a contributing fetal immune response (6, 7) . Over time, these insults may lead to ventricular dilation and hypertrophy, reduced ventricular compliance, and progressive EFE (22) . Myocardial damage may be clinically manifested with the development of progressive myocardial dysfunction, which includes systolic and likely diastolic components. Although diastolic dysfunction could not be evaluated in the presence of severe conduction disturbances in the present series, most had reduced or low-normal (in 3°AVB) SF before and/or after birth, suggesting systolic dysfunction. In 3°AVB, a normal cardiac output is maintained through increased stroke volume, which is likely not possible even with low-to-normal ventricular systolic function. We had included 4 cases with moderate-to-severe EFE but with normal-to-hyperdynamic ventricular systolic function as they had been treated with IVIG and corticosteroids in an effort to prevent the evolution of fetal or post-natal ventricular dysfunction. Although it is not certain these patients would have had progressive dysfunction, all continue to have echocardiographic evidence of EFE.
It has been suggested that certain pacemaker strategies after birth for 3°AVB contribute to the ventricular dysfunction in MAb-CM/EFE. DDD pacing, for instance, may not be tolerated particularly where intrinsic sinus rates are high, leading to detrimentally high ventricular rates (23); however, 5 of our patients were at least initially DDD paced in an effort to provide AV synchrony, and 3 have continued to be DDD paced longer term without recurrence of ventricular dysfunction. Resynchronization therapy, shown to be somewhat beneficial for affected infants (23), was used in 1 of our cases and could have contributed to improved function; however, this infant had significant dysfunction prior to pacing. IVIG in MAb-CM/EFE. Intravenous gamma globulin is established therapy for the treatment of autoimmune and inflammatory diseases such as SLE and Sjögren syndrome (24, 25) , and it is commonly used in the treatment of some cardiac disorders such as inflammatory CM and Kawasaki disease (26, 27) . The mode of action of IVIG is still under investigation but is believed to involve Fc-dependent and/or F(ab=)2-dependent nonexclusive mechanisms (11) . One animal study showed that maternal administration of IVIG to anti-Ro and anti-La positive mice significantly reduced the transplacental passage of these antibodies by nonspecific blockade of placental Fc receptors (28) . Studies in human pregnancies complicated by SLE (29) or MAb without clinical autoimmune disease but with a prior fetus with AVB (30) have shown normalization or significant reduction in circulating MAb in response to IVIG. In addition to reducing the ability of MAb to pass through the placenta, and reducing overall maternal circulating MAb levels, IVIG may also modulate immune system homeostasis through interaction with cytokines, complement, and cell surface immunocompetent molecules (11) to reduce the fetal immune-mediated myocardial damage.
In our experience, IVIG administration in MAb-CM/EFE is well tolerated. We recognize that maternal IVIG therapy, however, is not without risk, as it exposes both mother and fetus to blood products. Intraumbilical administration may reduce maternal exposure, but it is considerably more invasive. Waiting to administer IVIG post-natally, particularly in the less-compromised fetus, eliminates maternal exposure risks, but subjects the newborn infant to both a blood product and a large volume load in the setting of marginal ventricular function, particularly when the hemodynamic burden of the heart is already acutely increased with the transition to the neonatal circulation. More importantly, waiting to provide IVIG until after birth may eliminate the added benefits of reducing MAb exposure and myocardial damage in utero. Dexamethasone in MAb-CM/EFE. In addition to IVIG, dexamethasone was also administered pre-natally to most mothers in our series and was largely well tolerated. Problems with neurodevelopment and growth are potential side effects of pre-natal corticosteroid use (31), neither of which was noted in the clinical records of our patients. We justified the use of maternal dexamethasone in addition to IVIG for fetal MAb-CM/EFE as we have previously documented significant improvement in the outcomes of isolated fetal AVB (9) . Others have also shown improvement in fetal AV conduction following maternal dexamethasone administration in incomplete AVB (32) , and, in the present report, we observed improved AV conduction in 4 pre-natally treated pregnancies. It has been proposed that maternal dexamethasone may mitigate the immune-mediated cardiac inflammation provoked by MAb and indirectly improve cardiac contractility (33) . Dexamethasone is preferable to prednisone, as prednisone has not been shown to decrease MAb 721 JACC Vol. 57, No. 6, 2011
Trucco et al. February 8, 2011:715-23 IVIG in Immune-Mediated Fetal Cardiomyopathy levels and placental 11-beta-dehydrogenase prevents the active drug from entering the fetal circulation (34, 35) . Post-natal corticosteroid administration is not without risk with side effects of systemic hypertension, hyperglycemia, gastrointestinal complications, and impaired immune function. Two of our patients developed wound infections, both having received high-dose intravenous Solu-Medrol. Although we had observed no other potentially steroidrelated complication, we have used lower dose prednisone at least for less critically ill patients tapering the dose over the first few months of life. Study limitations. This study is limited in that it is a retrospective chart review of patients from multiple centers. There was no concurrent control group and, as such, historical controls were used for comparison, which introduces other potential variables in management. The frequency and dosing of IVIG and corticosteroids in mothers and infants were diverse and left to the discretion of the treating cardiologist, making it difficult to draw conclusions regarding optimal timing, dose, and frequency of their use. Furthermore, although all mothers had documented MAb, titers were not serially checked, and therefore, the impact of our treatment strategy on MAb production could not be assessed. Additionally, structural heart disease requiring surgical or transcatheter intervention was present in 4 patients, and the effect of this comorbidity on outcome cannot be assessed. Finally, EFE was diagnosed by echocardiography and not histologically; however, in our previous work, EFE detected by echocardiography consistently underestimated EFE severity documented pathologically (6,7).
Conclusions
Using IVIG and corticosteroids to treat MAb-CM/EFE may significantly improve the outcome of this devastating disease, the exact mechanism of which remains unclear. Further investigation with a prospective multicenter randomized trial, including the evaluation of maternal and neonatal titers before and after therapy, is warranted. However, given that this is a rare disease with a high morbidity and mortality, a randomized trial may continue to prove impractical.
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